🇺🇸 FDA
Patent

US 12350285

Compounds and methods for reducing ATXN3 expression

granted A61KA61K31/7115A61K31/7125

Quick answer

US patent 12350285 (Compounds and methods for reducing ATXN3 expression) held by Ionis Pharmaceuticals, Inc. expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/7115, A61K31/7125, A61P, A61P25/28